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What’s new? 
 Peer support, whether delivered using a one-to-one, group or combined approach, was 
associated with reduced inpatient care utilization and payments.  
 An intervention that combined individual and group peer-support had a consistent and 
potentially long-term impact on health payments.   
 These data support the incorporation of invitation to structured peer support into 
modern Type 2 diabetes management.  
 A two-part model adjusting patients’ potential probability of utilising the health 
system is a practical tool to evaluate the health payment accurately. 
 
Abstract 
Aim To investigate the impact of a low-cost diabetes peer-support intervention, aimed at 
reducing inpatient and outpatient care utilization and healthcare payments, by conducting a 
cohort study that followed up a randomized controlled trial. 
Methods A total of 1121 adults with Type 2 diabetes were recruited through general 
practices in Cambridgeshire and Hertfordshire, UK, and were followed up for 3.25 financial 
years after 8–12 months of one-to-one, group or combined diabetes peer support and usual 
care. Use of, and payments for inpatient and outpatient services were fully recorded in the 
follow-up. Adjusted mean inpatient and outpatient payments per person were estimated using 
a two-part model after adjusting for baseline characteristics. 
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Results The mean age of the recruited adults was 65.6±11.4 years, 60.4% were male, and 
16.8% were insulin-treated. Compared with the control group, less healthcare utilization 
(especially non-elective inpatient care and outpatient consultations) was observed in each of 
the intervention groups, particularly the combined intervention group. Over the course of 
3.25 financial years, significant reductions of 41% (£909.20 per head) were observed for 
overall inpatient payments (P<0.0001), 51% (£514.67 per head) for non-elective inpatient 
payments (P=0.005) in the combined intervention group, and 34% (£413.30 per head) and 
32% (£388.99 per head) for elective inpatient payments in the one-to-one (P=0.029) and 
combined intervention (P=0.048) groups, respectively. 
Conclusions Type 2 diabetes peer support, whether delivered using a one-to-one, group or 
combined approach was associated with reduced inpatient care utilization (particularly non-
elective admissions) and payments over 3.25 years. 
 
Introduction 
Diabetes is associated with morbidity and premature death [1]. The health economic burden 
attributable to diabetes and its complications is an increasing challenge [2].   The benefits of 
behavioural interventions on metabolic, mental health and psychological issues have been 
variable [3,4].    
Diabetes peer support involves people with diabetes assisting each other to improve their 
social, mental and physical wellbeing.  Peer support can be provided through individual or 
group approaches and either face-to-face, telephone or online contact.   Peer support is a low-
cost intervention, and has been suggested to reduce healthcare costs [4], including among 
people with Type 2 diabetes [5,6].  Analyses in studies on such interventions, however, either 
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were only based on patients over the study period, without consideration of  healthcare 
utilization across the whole study population [5], or findings were not derived from a trial [6]. 
The Randomized Controlled Trial of Peer Support in Type 2 Diabetes (RAPSID) was the 
largest randomized controlled trial (RCT) on Type 2 diabetes peer support to date [7].  The 
intervention was recently shown to be cost-effective during the trial, based on self-reported 
costs [8].   Medication costs were excluded as these were not collected in detail. 
In the present study, we aimed to investigate whether peer support reduces utilization of, and 
payments for, secondary care services over 3.25 years of follow-up, including a comparison 
of the impact of different approaches to face-to-face support (one-to-one, group or 
combination of both). The logic model to link peer support with hospitalization is presented 
in Fig. S1. 
 
Materials and Methods 
Research design, participants and intervention 
The design, methods and primary outcomes of the RAPSID trial have been published 
previously [7], including its CONSORT (Consolidated Standards of Reporting Trials) 
diagram [7].  Briefly, RAPSID was a 2×2 factorial cluster RCT comparing four groups of 
participants with Type 2 diabetes: one-to-one (individual) peer support; group peer support; 
combined one-to-one and group peer support; and a control group. Participants had been 
diagnosed with diabetes for at least 12 months.  Those with dementia or psychotic illness 
were excluded. Participants were recruited from communities across Cambridgeshire and 
neighbouring areas of Essex and Hertfordshire.  Follow-up data were only available for 
participants in Cambridgeshire and the neighbouring areas of Hertfordshire that are served by 
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the Cambridgeshire and Peterborough Clinical Commissioning Group. Clusters were defined 
by local government (‘parish council’) boundaries.  The intervention was developed after a 
pilot study [9], using a framework defined by Peers for Progress [10].  Peers who delivered 
peer support were termed 'peer support facilitators' and their selection, training, support and 
the overall programme are described elsewhere [7].   
The intervention involved peer support delivered by trained facilitators in a community 
venue.  Within the first 6 months, discussion focused on three essential elements of diabetes 
management; namely, overcoming practical obstacles encountered while dealing with 
diabetes, coping with the social and emotional aspects of diabetes, and the type of medical 
therapy used in caring for diabetes.  Just over 60% (61.4%) attended a session involving face-
to-face contact with a peer support facilitator [7], but most participants (92.6%) were at least 
in contact by telephone.  After this period, topics were discussed at the discretion of the peer 
support facilitator and peers.  A monthly meeting was held between peer support facilitators 
and a health professional (diabetes specialist nurse or dietitian) to discuss any issues that had 
arisen. 
The intervention lasted 8–12 months and was commenced and concluded, cluster by cluster, 
between 2 June 2011 and 12 April 2012.  Ethics approval was received from the 
Cambridgeshire REC2 Committee (10/H0308/72), and signed consent included agreement for 
access to hospital data.   
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Assessments and outcomes 
At baseline, demographic data, duration of diabetes and treatment information were collected 
by self-report. Each participant was followed up until June 2015 (0.91–4.07 years' follow-up 
from entry into the trial).   
Data on hospitalization [funded by the National Health Service (NHS) at public and private 
hospitals], accident and emergency department and outpatient visits within the 
Cambridgeshire and Peterborough Clinical Commissioning Group (CCG) catchment were 
collected through the CCG and classified into 3.25 financial years based on the CCG audit 
timeframe: 1) first financial year: April 2012 to March 2013; 2) second financial year: April 
2013 to March 2014; and 3) last 1.25 financial year: April 2014 to June 2015. The 
elective/non-elective status, International Classification of Diseases (ICD-10) codes, Health 
Related Group codes and Office of Population Censuses and Surveys Version-4 (OPCS-4) 
procedure codes for each episode for the above hospital-based healthcare were recorded by 
hospital staff and each would have attracted a nominated tariff or payment [11]. 
Hospitalization (NHS hospitals and private hospitals), accident and emergency department 
and outpatient visits were classified according to elective/non-elective status and primary 
reasons (cardiovascular disease and diabetes-related disorders), as defined by ICD-10 codes. 
Health payments were defined by Health Related Group group and OPCS-4 codes; however, 
these often do not cover the provider ‘cost’ of the care for people with diabetes [12] and the 
term ‘health payments’ is therefore used.    
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Statistical analysis 
A large proportion of the population do not attend hospital as an inpatient or outpatient in any 
given year and therefore healthcare payment data demonstrate a skewed utilization/payment 
pattern [13]. To take into account the problem of ‘zero mass’ and skewed outcomes, the 
demand functions were modelled using a two-part model [14]. In this two-part model, a 
probit model was estimated for the probability of observing 'zero' vs positive medical 
expenditure. Positive medical expenditure is defined as any healthcare expenditure greater 
than zero. A generalized linear model was estimated, conditional on having healthcare 
expenditure. The generalized linear model was used, instead of log ordinary least squares 
regression, because it relaxes the normality and homoscedasticity assumption, and avoids 
bias associated with re-transforming to the raw scale [15]. The results of the modified Park 
test [14] verified that the use of a gamma distribution, with a log link, was the best fitted 
generalized linear model for consistent estimation of coefficients and marginal effects of 
medical expenditure [16]. Multicollinearity was tested for predictors of the two-part model, 
taking into account the complex survey design [13]. The variance inflation factor for all 
predictors used in the two-part model indicated no-existence of multicollinearity [17]. The F-
test for the two-part regression models was found to be significant, which indicated the 
overall significance of the regression model. Marginal effects were then estimated as the 
mean health payment from the combined first and second parts of the final model [16]. The 
payment ratio for each intervention group compared with the control group was also 
calculated. To control for confounding, baseline characteristics were included in the fully 
adjusted model (Table 1). The 95% CIs for estimated payments were estimated using a 
bootstrap process with 1000 samples. In the sensitivity analysis, all analyses were repeated 
for each financial year.   All analyses were performed with STATA (STATA/SE 14.0 
StataCorp, College Station, TX, USA). 
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Results 
Baseline characteristics 
Overall, 1121 patients in Cambridgeshire/Hertfordshire were recruited and randomized across 
120 clusters. Baseline data for the four arms were well matched (Table 1). The majority of 
participants reported antihypertensive (727; 65%), lipid-lowering (752; 67%) and diabetes 
medication (892; 80%). Compared with those without, participants with an endpoint HbA1c 
were older [mean (SD) 65 (9) vs 63 (10) years; P = 0.018], had longer diabetes duration 
[mean (SD) 9 (11) vs 8 (8) years; P = 0.016], lower BMI [mean (SD) 31.9 (6.8) vs 33.6 (6.7) 
kg/m
2
; P < 0.001] and were more likely to be treated with anti-hyperglycaemic tablets (81.6% 
vs 73.2%;  P = 0.004), hypertension treatment (66.2 vs 59.4%; P = 0.004) and lipid-lowering 
treatment (68.5% vs 60.7%; P = 0.021) at baseline.  
 
Health service payments 
Health payment data were typically skewed (Table 2) as a result of the mass of ‘zero’ 
payments and a relatively small proportion of patients incurring extremely high expenditure. 
Between 2012 and June 2015, 54.30% of controls and 62.45%, 60.76% and 61.57% of 
participants in the one-to-one group, and combined intervention groups, respectively, were 
associated with zero inpatient payments. Among patients hospitalized in the period April 
2012 to June 2015, the median (interquartile range) inpatient payments were £2488.42 
(1118.57 to 5198.51), £2201.20 (846.38 to 5704.23), £2009.06 (888.53 to 5169.54) and 
£2421.94 (903.20 to 5236.43) for the control, one-to-one, group, and combined intervention 
groups, respectively. Outpatient attendance was relatively common in each group, with 
33.68%, 39.46%, 35.76% and 39.15% of patients attending in the control, one-to-one, group, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
and combined intervention group, respectively. The median (interquartile range) outpatient 
payments were also skewed at £708.04 (316.75 to 1461.71), £645.22 (268.32 to 1270.91), 
£657.54 (285.58 to 1407.21), and £757.41 (320.77 to 1255.93) for the control, one-to-one, 
group, and combined intervention groups, respectively. 
Similar patterns of health payment distribution in the financial years 2012–2013, 2013–2014 
and 2014–June 2015 were found (Table S1). 
 
Results from the two-part model 
The results of the final two-part models are shown in Table 3. In the follow-up period 2012–
June 2015, compared with patients in the control group and based on logit model estimations, 
significantly lower overall inpatient hospitalization was observed in the group intervention 
(P=0.033). The rate of non-elective hospitalization was significantly lower in the group 
(P=0.009) and combined (P=0.029) interventions.  A lower rate of hospitalization for 
cardiovascular disease was found in the combined intervention and for diabetes in the one-to-
one (P<0.0001) and combined (P=0.021) interventions.  There were no reductions in 
outpatient utilization or costs. 
Compared with patients in the control group, based on generalized linear model estimation, 
payments for overall inpatient hospitalization was more likely to be reduced in the combined 
intervention (P<0.0001). Reduced payments for elective hospitalization were observed in the 
one-to-one (P=0.029) and combined interventions (P=0.048). Reduced payments for non-
elective hospitalization were observed in the combined intervention (P=0.005) and for 
hospitalization for diabetes with the group intervention (P=0.015).  
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Sensitivity analysis was carried out in each calendar year and similar findings were observed, 
especially in the financial years 2013–2014 and 2014–June 2015 (Table S2). 
 
Estimated mean inpatient and outpatient payments 
Inpatient and outpatient payments, with payment ratios by intervention group, were estimated 
from the combined first and second parts of the two-part model with adjustment of baseline 
characteristics (Tables 3 and 4). In comparison with the control group, significantly lower 
overall inpatient payments were observed in the combined intervention group for the period 
April 2012–June 2015 [payment ratio = 0.59 (41% of saving = £909.20 per head; P<0.0001)]. 
A significant elective inpatient payment reduction was found both for the one-to-one 
intervention [payment ratio = 0.66 (34% of saving = £413.30 per head; P=0.029)] and the 
combined intervention [payment ratio = 0.68 (32% of saving = £388.99 per head; P=0.048)], 
respectively. A significant non-elective inpatient payment reduction was observed only for 
the combined intervention [payment ratio = 0.49 (51% of saving = £514.67 per head; P = 
0.005)]. 
In the sensitivity analysis (Tables 2 and 3), overall inpatient payment reduction was 
statistically significant in the financial year 2013–2014 for the combined intervention 
[payment ratio = 0.49 (51% of saving = £749.87 per head, P=0.004)]. Elective inpatient 
payment reduction was statistically significant in the financial year 2013–2014 for both the 
one-to-one intervention [payment ratio = 0.54 (46% of saving = £374.12 per head; P=0.033)] 
and combined intervention [payment ratio = 0.53 (47% of saving = £382.25 per head; 
P=0.008)].  A reduction in payment for hospitalization primarily attributable to diabetes was 
observed in the financial year 2013–2014 for the combined intervention group [payment ratio 
= 0.48 (52% reduction= £211.80 per head; P=0.010)].  
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Discussion 
The RAPSID intervention produced sustained reductions in inpatient service utilization and 
healthcare payments compared with the control group over the 3.25 years of follow-up after 
the intervention.   This is in contrast to an absence, or weak effects on primary (HbA1c) or 
secondary outcomes (e.g. diabetes distress, medication adherence, depression, quality of life, 
weight, self-efficacy, diabetes knowledge), except blood pressure, as previously identified in 
RAPSID [7], and the effects were observed particularly with the combined intervention.   
Elective inpatient healthcare payments and inpatient healthcare payments primarily 
attributable to cardiovascular diseases were significantly lower in the intervention groups. 
The consistently lower inpatient healthcare payments were observed in the combined 
intervention group in each financial year.   
The present RAPSID study was well-powered to test its hypothesis, not only because it 
achieved its recruitment targets and size, but also because of its high retention rates. The 
intervention was fully implemented, with high fidelity, having established peer support and 
delivered the planned content in almost all areas. Another strength of the present study is the 
minimal information bias regarding the outcome used in this study; both inpatient and 
outpatient payments were fully recorded by the CCG [11]. In particular, as these are payment 
details, both NHS hospitals and private hospital admissions were recorded.   There would 
have been some loss for patients where no component of care was paid for by the CCG.   
The study also has some limitations which should be considered when interpreting the 
findings.  Unlike pharmaceutical interventions, where adherence can be assessed using pill 
counters, it is difficult to evaluate the magnitude of a peer-support intervention on an 
individual level, and although we did record attendance and telephone calls, we did not assess 
engagement.  Although the follow-up time was relatively short in the study, especially with 
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only a half-year health payment available in the third financial year, this is still the longest 
follow-up after an RCT to date in diabetes peer-support trials. The payment/savings from 
similar peer-support interventions should be further investigated in other post-trial 
observation studies.   A further limitation of the study is that we were unable to describe the 
activities of participants after the trial was completed.  All participants were sent the results, 
and we are aware that some interventions (e.g. peer-support groups) continued, with support 
from the Diabetes UK 'Type 2 Together' programme [18].   Further limitations include the 
lack of data relating to medication costs, for example, and default from hospital and other 
appointments, and that the study cohort may be atypical with its relatively ‘good’ mean 
HbA1c, ethnic homogeneity and greater proportion of professional/managerial participants.  
The number of participants with a higher HbA1c [≥8% (64 mmol/mol), n=272] were too few 
to assess whether the peer-support effect on utilization/payments was greater in these 
participants than in those with less hyperglycaemia, although HbA1c was not a significant 
entrant in the multivariate analyses (Table 3).  The presence of diabetes-related complications 
was not formerly assessed, and self-report was not considered robust enough to differentiate 
between presence/absence and significant/less significant severity (e.g. background vs 
proliferative retinopathy). Furthermore, as an observation study, there might be some 
unknown confounders that could have some impact on the post-trial healthcare utilization and 
health payments. Further validation studies are warranted. 
The clinical effectiveness of peer-support interventions among people with Type 2 diabetes 
has been identified by several trials [19,20]. For example, Tang et al. [21] reported that 
Latino adults with Type 2 diabetes in a peer-led intervention group achieved a reduction in 
mean HbA1c that was maintained at 18 months. In RAPSID, a reduction in blood pressure 
was identified in the combined intervention group [7]. Few studies, however, have addressed 
the payment/savings for inpatient and outpatient expenditure as a result of peer-support 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
interventions.  Our original cost-effectiveness study showed cost-saving, but this was based 
on self-reported utilization data and only at the end of the trial [8].   One group-based peer-
support intervention trial in Ireland found that a group-based peer-support intervention led to 
a €637.43 of lifetime saving in health payment [22]. In another Austrian trial, the 24 months’ 
group-based peer support intervention reduced the length of hospital stay, which was 
estimated as €1660.60 per patient [5]. The present study is the first study to show payment 
reductions/savings of £350.76 of (£306.71 for inpatient and £44.05 for outpatient) at 3.25 
years after the intervention had been completed.  Although the study design and populations 
were different and chance of utilization of healthcare was not taken into consideration in most 
studies, these findings evidently support the application of peer-support interventions in 
people with Type 2 diabetes. Another study [6] reported that non-healthcare costs were 
reduced during the 3 years after implementation of the peer-support intervention, but these 
findings were not derived from an RCT [6].  
 
 In the present study, compared with the control group, reductions in hospitalization and 
relevant payments were observed in the group and combined interventions. In the JADE and 
PEARL programmes in Hong Kong, hospitalization was reduced among those with high 
diabetes distress, suggesting a raised threshold for attendance for non-elective care (i.e. 
reduced healthcare-seeking) [23].    
 
Although the decline in outpatient consultation in the intervention group might also reflect a 
reduced likelihood of healthcare-seeking as a result of increased support or knowledge of 
diabetes through the peer-support intervention [4], no  reductions in outpatient utilization and 
payments were observed in the present study.  Conversely, in the JADE and PEARL studies 
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outpatient attendances were reduced by 16% with their peer-support group intervention [23]. 
The authors explained this by suggesting that peer support reduced non-adherence and 
negative emotions among people with diabetes, which contributed to their low rate of 
hospitalization.  
Hospitalization for cardiovascular diseases occurred less frequently in the combined 
intervention, which might be attributed to the significant improvement in blood pressure 
during the trial, with a mean systolic blood pressure reduction of 2–3 mmHg [7]. Another 
explanation could be an improvement in chronic disease self-management behaviour, as 
observed in a 6-month study, in which patients with multiple morbidities who received 
coaching on chronic disease self-management had healthier behaviour and health status (and 
spent 0.8 fewer hospital nights) compared with the control group [24]. In a US study, lower 
levels of family and social support and mental illness were associated with frequent 
hospitalization [25].   Apart from reduced blood pressure, we found no other possible 
mechanisms for the reduced hospitalization rate (Fig. S1), although not all pathways could be 
tested. 
The impact of reduced utilization of healthcare and associated health expenditure/payments 
suggests an additive effect of individual peer-support intervention and group peer-support 
intervention, which may indicate that long-term health economic benefits could be expected 
by combining individual and group peer-support interventions [3,4]. 
In conclusion, random assignment of people with Type 2 diabetes to different peer-support 
interventions resulted in less utilization of inpatient and outpatient care and reduced payments 
for inpatient and outpatient attendances in the 3.25 years after the interventions. Combining 
individual and group peer-support intervention had the most consistent and potentially long-
term impact on health payments.  Commissioners/funders should consider including diabetes 
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peer support as part of their local diabetes programme.  Further studies should evaluate 
approaches to scale up the RAPSID approach.  
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Figure S1. Logic model of study hypotheses to link diabetes peer support with reduced 
hospitalization. 
Table S1. Distribution of inpatient and outpatient cost by intervention group in 
Cambridgeshire, by financial year 
Table S2. Adjusted estimations from two-part models that modelling health cost by 
intervention group, analysis among patients resident in Cambridgeshire, by financial year. 
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Table S3. Estimated mean health cost from two-part models accounting for probability of 
generating health cost with adjustment of  covariables, analysis among patients resident in 
Cambridgeshire, by financial year. 
 
Table 1 Baseline characteristics of participants by intervention assignment 
 
Intervention 
 
Control 
 N=291 
One-to-one 
N=261 
Group 
N=288 
Combined 
N=281 
Males, n (%) 168 (57.7) 158 (60.5) 190 (66.0) 164 (58.4) 
Mean (SD) age, years 65.9 (12.9) 65.0 (9.7) 66.0 (11.8) 65.8 (10.3) 
Median (IQR) duration of diabetes, years 6.5 (3.0 to 12.0) 7.0 (3.0 to 12.0) 7.0 (3.0 to 12.0) 6.0 (3.0 to 11.0) 
Profession/managerial, n (%) 195 (67.0) 176 (67.4) 193 (67.0) 186 (66.2) 
Married/cohabiting, n (%) 218 (74.9) 196 (75.1) 227 (78.8) 213 (75.8) 
Self-reported smoking, n (%) 34 (11.7) 24 (9.2) 25 (8.7) 23 (8.2) 
Insulin treated, n (%) 42 (14.4) 52 (19.9) 46 (16.0) 48 (17.1) 
Diabetes tablets, n (%) 223 (76.6) 230 (88.1) 226 (78.5) 213 (75.8) 
Insulin and tablets, n (%) 31 (10.7) 17 (6.7) 36 (12.5) 34 (12.1) 
Hypertension treatment, n (%) 174 (59.8) 185 (70.9) 181 (62.8) 187 (66.5) 
Dyslipidaemia treatment, n (%) 180 (61.9) 186 (71.3) 191 (66.3) 195 (69.4) 
Mean (SD)  BMI, kg/m
2
 32.3 (6.2) 32.6 (6.3) 32.1 (5.9) 32.1 (5.9) 
Mean (SD) HbA1c 
mmol/mol  
% 
 
56.8 (12.7) 
7.3 (1.2) 
 
57.6 (13.3)  
7.4 (1.2) 
 
58.1 (13.0)  
7.5 (1.2) 
 
56.1 (12.8)  
7.3 (1.2) 
Mean (SD) systolic blood pressure, mmHg 140.3 (18.1) 140.6 (18.3) 141.7 (17.3) 139.4 (16.7) 
Mean (SD) diastolic blood pressure, mmHg 75.5 (10.6) 76.1 (9.7) 75.6 (10.2) 76.4 (9.5) 
Mean (SD) total cholesterol, mmol/l 4.41 (1.07) 4.39 (1.01) 4.33 (1.07) 4.41 (1.06) 
IQR, interquartile range. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2 Distribution of inpatient and outpatient health payments in financial years 2012 to June 2015, by intervention group  
  
  
Median cost (interquartile range of cost), £ People with zero payment 
among people with non-zero payment N (%) 
Control  One-to-one Group Combined Control 
 One-to-
one Group Combined 
Overall inpatient cost 2488.42 (1118.57 to 5198.51) 2201.20 (846.38 to 5704.23) 2009.06 (888.53 to 5169.54) 2421.94 (903.20 to 5236.43) 
158 
(54.30) 
163 
(62.45) 
175 
(60.76) 
173 
(61.57) 
Elective inpatient cost   1644.17 (877.25 to 3961.06) 1429.20 (668.33 to 3445.25) 1459.23 (763.34 to 3883.17) 1506.72 (636.02 to 3873.66) 
177 
(60.82) 
182 
(69.73) 
189 
(65.63) 
189 
(67.26) 
Non-elective inpatient cost  2565.61 (790.34 to 6243.07) 3167.88 (1050.70 to 5984.87) 2198.81 (790.22 to 5837.33) 2749.98 (742.39 to 4758.61) 
226 
(77.66) 
224 
(85.82) 
240 
(83.33) 
235 
(83.63) 
Inpatient cost primarily due to 
cardiovascular diseases  2128.20 (826.03 to 4819.95) 2307.62 (1005.11 to 5511.12) 1892.40 (771.58 to 4442.97) 2995.68 (770.69 to 3961.41) 
225 
(77.32) 
216 
(82.76) 
235 
(81.60) 
240 
(85.41) 
Inpatient cost primarily due to 
diabetes  1118.57 (664.57 to 2705.06) 1310.61 (743.24 to 4276.81) 1230.32 (560.84 to 3607.65) 1381.61 (694.51 to 3048.72) 
217 
(74.57) 
231 
(88.51) 
226 
(78.47) 
225 
(80.07) 
Overall outpatient cost  708.04 (316.75 to 1461.71) 645.22 (268.32 to 1270.91) 657.54 (285.58 to 1407.21) 757.41 (320.77 to 1255.93) 
98 
(33.68) 
103 
(39.46) 
103 
(35.76) 
110  
(39.15) 
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Table 3 Adjusted estimations from two-part models of healthcare payment by intervention group: analysis among patients resident in Cambridgeshire, for the 
financial years 2012 and June 2015 
  
 One-to-one Group Combined 
Logit GLM Logit GLM Logit GLM 
Coefficient SE P Coefficient SE P Coefficient SE P Coefficient SE P Coefficient SE P Coefficient SE P 
Overall inpatient 
payment  
–0.122 0.074 0.100 –0.147 0.115 0.203 –0.156 0.073 0.033 0.003 0.146 0.986 –0.145 0.074 0.051 –0.374 0.106 <0.0001 
Elective inpatient 
payment   
–0.129 0.077 0.092 –0.272 0.125 0.029 –0.127 0.075 0.090 –0.078 0.139 0.573 –0.139 0.076 0.068 –0.226 0.114 0.048 
Non-elective inpatient 
payment  
–0.167 0.085 0.051 0.138 0.156 0.378 –0.220 0.084 0.009 0.236 0.196 0.230 –0.186 0.085 0.029 –0.424 0.152 0.005 
Inpatient payment 
primarily due to 
cardiovascular 
diseases  
–0.069 0.085 0.415 0.232 0.149 0.120 –0.148 0.084 0.078 –0.142 0.145 0.329 –0.263 0.088 0.003 –0.013 0.151 0.929 
Inpatient payment  
primarily due to 
diabetes  
-0.309 0.086 <0.0001 0.163 0.148 0.270 -0.147 0.081 0.069 0.386 0.159 0.015 -0.193 0.083 0.021 -0.151 0.134 0.261 
Overall outpatient 
payment  
–0.070 0.072 0.330 –0.068 0.062 0.272 –0.075 0.071 0.292 –0.039 0.057 0.498 –0.069 0.072 0.334 –0.050 0.061 0.417 
GLM, generalized linear model. 
Two-part models model the probability of generating health payment (probit) separately from the payment of healthcare conditional on having been hospitalized or consulted at least once 
(GLM), adjusted for baseline characteristics (age, gender, duration of diabetes, occupation, marital status, diabetes treatment, hypertension treatment, dyslipidaemia treatment, BMI, HbA1c, 
systolic blood pressure, diastolic blood pressure, total cholesterol and BMI. SE derived by bootstrapping method. 
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Table 4 Estimated mean health payment from two-part models accounting for probability of generating health payment after adjustment for covariates among 
patients resident in Cambridgeshire, in the financial years 2012 to June 2015 
 
Estimated health payment, (95% CI) 
Payment ratio 
 Control One-to-one Group Combined Control 
One-to-
one 
Group Combined 
Overall inpatient payment, £ 
2217.57 (1789.32 to 
2645.81) 
1675.21 (1330.24 to 
2020.19) 
1872.29 (1377.75 to 
2366.83) 
1300.80 (1056.80 to 
1544.80) 
1 0.76 0.84 0.59 
Elective inpatient payment, £  
1215.60 (956.25 to 
1474.95) 
797.52 (623.48 to 
971.56) 
970.61 (735.64 to 
1205.58) 
824.61 (649.76 to 
999.47) 
1 0.66 0.80 0.68 
Non-elective inpatient payment, £ 
1009.15 (745.42 to 
1272.88) 
902.72 (631.45 to 
1174.00) 
915.26 (556.40 to 
1274.12) 
499.21 (353.23 to 
645.20) 
1 0.89 0.91 0.49 
Inpatient payment primarily attributable to 
cardiovascular diseases, £  
714.76 (522.17 to 907.35) 
817.13 (600.85 to 
1033.40) 
500.66 (366.32 to 
634.99) 
476.35 (329.45 to 
623.25) 
1 1.14 0.70 0.67 
Inpatient payment primarily attributable to 
diabetes, £ 
514.42 (387.03 to 641.81) 
390.16 (277.01 to 
503.32) 
618.74 (438.71 to 
798.77) 
338.98 (254.87 to 
423.09) 
1 0.76 1.20 0.66 
Ov rall outpatient payment, £ 
846.46 (764.18 to 928.75) 
761.98 (681.89 to 
842.07) 
783.12 (712.51 to 
853.72) 
776.91 (698.74 to 
855.08) 
1 0.90 0.93 0.92 
Two-part models model the probability of generating health payment (probit) separately from the payment of healthcare conditional on having been hospitalized or consulted at least once 
(generalized linear model), adjusted for baseline characteristics (age, gender, duration of diabetes, occupation, marital status, diabetes treatment, hypertension treatment, dyslipidaemia 
treatment, BMI, HbA1c, systolic blood pressure, diastolic blood pressure, total cholesterol and BMI). CI was derived by bootstrapping method.  
 
 
 
